With an ever increasing number of patients being treated with IVIg for a wide array of immune-mediated disease, it is important that passive antibody ... have on subsequent blood tests, and ...

Discover a recent study presented at EASL 2025 that explored the impact of opt-out testing for blood-borne viruses in ...

antinuclear antibody titre ≥1:320, evidence of hepatitis B, hepatitis C or HIV infection, known sensitivity to methotrexate (MTX), sulphasalazine or hydroxychloroquine and systemic disease likely to ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

Discover an awarding winning abstract from EASL 2025 that has called for more person-centred hepatitis screening. Learn more.

“This launch of opt-out testing for blood-borne viruses will allow us to identify many more cases of HIV, hepatitis B, and hepatitis C within the community. “Often, patients have no symptoms ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued stocks in the Pharmaceuticals industry for Friday, May 09, 2025. Let’s take a ...

The anguish is beyond words. I just want this over.” Mr Evans, who was infected with HIV and hepatitis C through contaminated blood products during treatment for haemophilia as a child ...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis ... from the blood and remains undetectable after stopping all treatment. In B-Clear, patients with ...